Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.48 |
| ▸ | EGFR | P00533 | 11/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.47 |
| ▸ | ABL1 | P00519 | 9/20 | 0.47 |
| ▸ | HCK | P08631 | 9/20 | 0.47 |
| ▸ | KDR | P35968 | 9/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.47 |
| ▸ | MTOR | P42345 | 9/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 9/20 | 0.47 |
| ▸ | PRKDC | P78527 | 9/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 9/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14471400 | 0.84 | SRC (0.56) | SRCPIK3CDKDRPIK3CAMTOR | |
| SCHEMBL14471392 | 0.82 | SRC (0.51) | SRCKDRMTORFYNBTK | |
| SCHEMBL14471397 | 0.76 | SRC (0.62) | SRCEGFRPIK3CDABL1HCK | |
| SCHEMBL14471391 | 0.71 | SRC (0.58) | SRCEGFRPIK3CDABL1HCK | |
| SCHEMBL3630418 | 0.70 | SRC (0.76) | SRCEGFRPIK3CDABL1HCK | |
| SCHEMBL24096759 | 0.70 | SRC (0.60) | SRCEGFRPIK3CDABL1HCK | |
| SCHEMBL12436456 | 0.69 | SRC (0.76) | SRCEGFRPIK3CDABL1HCK | |
| SCHEMBL23035193 | 0.68 | SRC (0.70) | SRCEGFRPIK3CDABL1PIK3CA | |
| SCHEMBL14471399 | 0.67 | SRC (0.56) | SRCEGFRPIK3CDABL1HCK | |
| SCHEMBL12436142 | 0.67 | RET (0.63) | SRCEGFRPIK3CDABL1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | RHODE ISLAND BOARD OF EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | DSTYK, SRC, PTK2B | SRC 2/4885EGFR 703/4885PIK3CD 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.